Antiviral Therapy of CMV Disease in Children
- 3 September 2010
- book chapter
- Published by Springer Nature
- Vol. 697, 243-260
Abstract
Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in infants and children. The main burden of disease occurs in congenital infection, postnatal infection in premature infants and in older immunocompromised children (now predominantly following transplantation) in developed countries. In lower income countries, CMV is a major co-pathogen in human immunodeficiency virus [HIV]-infected infants. Antiviral treatment options remain very limited. The guanosine analogue ganciclovir (GCV) was first used in children over 20 years ago, but the optimal dose, duration and route of administration remain poorly evidence based. In particular there are very limited data in premature infants and older children. Direct comparison studies between the intravenous ganciclovir and the oral valyl-ester valganciclovir (VGCV) have not been performed. CMV disease is important, but not very common and there remains a need to identify useful surrogate markers of successful antiviral therapy to facilitate clinical trials. Cidofovir and foscarnet have very significant toxicity. No other anti-CMV agent has successfully completed phase III studies. There remain few other antiviral agents effective against CMV on the horizon. This chapter reviews the current clinical spectrum of CMV disease in childhood and the evidence base for both GCV and VGCV use in clinical practice. It also discusses the antiviral studies currently being performed and those that need to be performed.Keywords
This publication has 63 references indexed in Scilit:
- Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous systemJournal of Clinical Virology, 2009
- Cytomegalovirus Blood Viral Load and Hearing Loss in Young Children With Congenital InfectionThe Pediatric Infectious Disease Journal, 2009
- Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus DiseaseThe Journal of Infectious Diseases, 2008
- Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infantJournal of Perinatology, 2007
- Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive studyThe Lancet, 2007
- Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing LossThe Journal of Pediatrics, 2005
- Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: A two-regimen experienceThe Journal of Pediatrics, 1994
- Sequelae of acquired cytomegalovirus infection in premature and sick term infantsThe Journal of Pediatrics, 1985
- Postnatally acquired cytomegalovirus infections in infants of CMV-excreting mothersThe Journal of Pediatrics, 1984
- Breast Milk and the Risk of Cytomegalovirus InfectionNew England Journal of Medicine, 1980